A Safety and Efficacy Trial of Docetaxel With or Without XH1 in Non-small Cell Lung Cancer (NSCLC) Patients

NCT03407300 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer (NSCLC)

Interventions

DRUG: Docetaxel
DRUG: Chinese traditional medicine XH1

Sponsor

Haining Health-Coming Biotech Co., Ltd.

Collaborators

[object Object]